IVVD NASDAQ
Invivyd, Inc.
1W: -10.9%
1M: +3.5%
3M: -0.2%
YTD: -66.7%
1Y: -31.8%
3Y: -53.5%
5Y: -98.1%
$0.82
+0.01 (+0.69%)
Weekly Expected Move ±21.5%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (53)
Invivyd drops after delaying late-stage trial data for COVID therapy
Invivyd, Inc. $IVVD Stock Sold by Squarepoint Ops LLC
BlackRock Inc. Takes $14.08 Million Position in Invivyd, Inc. $IVVD
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
SkinHealth Systems Inc. (SKIN) Reports Q2 Loss, Lags Revenue Estimates
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
Invivyd to Participate in Upcoming Investor Events
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
Brokerages Set Invivyd, Inc. (NASDAQ:IVVD) PT at $8.00
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Invivyd rises after update from late-stage trial for COVID therapy
12 Health Care Stocks Moving In Thursday's Intraday Session
BlackBerry Posts Upbeat Q4 Results, Joins Constellation Brands, Marvell Technology And Other Big Stocks Moving Higher On Thursday
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages
12 Health Care Stocks Moving In Monday's After-Market Session
Invivyd Announces Presentation at the World Vaccine Congress Washington
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages
12 Health Care Stocks Moving In Friday's After-Market Session
Invivyd outlines mid-2026 pivotal data timeline for VYD2311 as DECLARATION study reaches target enrollment
Invivyd (IVVD) Q4 2025 Earnings Call Transcript
Invivyd Q4 Earnings Assessment
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
Earnings Scheduled For March 5, 2026
Here are the major earnings before the open Thursday
An Overview of Invivyd's Earnings
Invivyd FY 2025 Earnings Preview
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
Invivyd (NASDAQ:IVVD) Shares Up 10.6% – What’s Next?
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness